Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Servier
Servier
Janssen Research & Development, LLC
Hoffmann-La Roche
Bristol-Myers Squibb
Incyte Corporation
Neonc Technologies, Inc.
Tizona Therapeutics, Inc
Charite University, Berlin, Germany
University of Alabama at Birmingham
Fondazione Policlinico Universitario Agostino Gemelli IRCCS